Structural determinants of HERG channel block by clofilium and ibutilide

Molecular Pharmacology

Volumn 66, Issue 2, 2004, Pages 240-249

  Perry, Matthew ^a   De Groot, Marcel J ^b   Helliwell, Ray ^b   Leishman, Derek ^b   Tristani Firouzi, Martin ^c   Sanguinetti, Michael C ^d   Mitcheson, John ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CLOFILIUM; IBUTILIDE; IBUTILIDE FUMARATE; MESYLIC ACID DERIVATIVE; METHANESULFONANILIDE; PHENYL GROUP; PHENYLALANINE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG STRUCTURE; FEMALE; HEART ARRHYTHMIA; HEART REPOLARIZATION; HYPERPOLARIZATION; LONG QT SYNDROME; MOLECULAR MODEL; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN DOMAIN; SITE DIRECTED MUTAGENESIS; VOLTAGE CLAMP; XENOPUS LAEVIS;

AMINO ACID SUBSTITUTION; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ASPARTIC ACID; BENZOPYRANS; BINDING SITES; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; KINETICS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; OOCYTES; PHENETHYLAMINES; PHENYLALANINE; PIPERIDINES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; PYRIDINES; QUATERNARY AMMONIUM COMPOUNDS; SERINE; SULFONAMIDES; TYROSINE; XENOPUS LAEVIS;

EID: 3342988006     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.000117     Document Type: Article

References (31)

1. Armstrong CM (1968) Induced inactivation of the potassium permeability of squid axon membranes. Nature (Lond) 219:1262-1263.
2. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 262:809-817.
3. + current by almokalant in rabbit ventricular myocytes. Circ Res 73: 857-868.
4. Castle NA (1991) Selective inhibition of potassium currents in rat ventricle by clofilium and its tertiary homolog. J Pharmacol Exp Ther 257:342-350.
5. + channel blockers. J Med Chem 45:3844-3853.
6. Crumb W and Cavero II (1999) QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharm Sci Technol Today 2:270-280.
7. + channel and its structural implications. Nature (Lond) 403:321-325.
8. Dougherty DA (1996) Cation-pi interactions in chemistry and biology: a new view of benzene, Phe, Tyr and Trp. Science (Wash DC) 271: 163-168.
9. + conduction and selectivity. Science (Wash DC) 280:69-77.
10. Fermini B and Fossa AA (2003) The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2:439-447.
11. Gessner G and Heinemann SH (2003) Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241. Br J Pharmacol 138: 161-171.
12. + channel. Nature (Lond) 423:33-41.
13. Jiang YX, Lee A, Chen JY, Cadene M, Chait BT, and MacKinnon R (2002) The open pore conformation of potassium channels. Nature (Lond) 417:523-526.
14. + channels by vesnarinone. Mol Pharmacol 60:244-253.
15. Keating MT and Sanguinetti MC (2001) Molecular and cellular mechanisms of cardiac arrhythmias. Cell 104:569-580.
16. Lees-Miller JP, Duan Y, Teng GQ, and Duff HJ (2000) Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol 57:367-374.
17. Milnes JT, Crociani O, Arcangeli A, Hancox JC, and Witchel HJ (2003) Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 139:887-898.
18. Mitcheson JS, Chen J, Lin M, Culberson C, and Sanguinetti MC (2000a) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97:12329-12333.
19. Mitcheson JS, Chen J, and Sanguinetti MC (2000b) Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J Gen Physiol 115:229-240.
20. Mitcheson JS and Perry MD (2003) Molecular determinants of high-affinity drug binding to HERG channels. Curr Opin Drug Discov Dev 6:667-674.
21. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, et al. (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32-45.
22. Roden DM (1998) Mechanisms and management of proarrhythmia. Am J Cardiol 82:49I-57I.
23. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, and Vincent GM (1996) Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps and future directions. The SADS Foundation Task Force on LQTS. Circulation 94: 1996-2012.
24. Roy M, Dumaine R, and Brown AM (1996) HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94:817-823.
25. Sanchez-Chapula JA, Ferrer T, Navarro-Polanco RA, and Sanguinetti MC (2003) Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol Pharmacol 63:1051-1058.
26. + channel block. J Biol Chem 277:23587-23595.
27. Kr potassium channel. Cell 81:299-307.
28. Sanguinetti MC and Xu QP (1999) Mutations of the S4-S5 linker alter activation properties of HERG potassium channels expressed in Xenopus oocytes. J Physiol 514:667-675.
29. Kr: the hERG channel. J Mol Cell Cardiol 33:835-849.
30. + channels: friend and foe. Trends Pharmacol Sci 22:240-246.
31. Kr) in AT-1 cells. Concentration-, time-, voltage- and use-dependent effects. Circulation 91:1799-1806.